KR20210142681A - 재조합 ccn 도메인 단백질 및 융합 단백질 - Google Patents

재조합 ccn 도메인 단백질 및 융합 단백질 Download PDF

Info

Publication number
KR20210142681A
KR20210142681A KR1020217033515A KR20217033515A KR20210142681A KR 20210142681 A KR20210142681 A KR 20210142681A KR 1020217033515 A KR1020217033515 A KR 1020217033515A KR 20217033515 A KR20217033515 A KR 20217033515A KR 20210142681 A KR20210142681 A KR 20210142681A
Authority
KR
South Korea
Prior art keywords
seq
ser
val
glu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217033515A
Other languages
English (en)
Korean (ko)
Inventor
호바르드 아트라마달
올레 외르겐 코스뵐
Original Assignee
오슬로 유니버시테시케후스 에이치에프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오슬로 유니버시테시케후스 에이치에프 filed Critical 오슬로 유니버시테시케후스 에이치에프
Publication of KR20210142681A publication Critical patent/KR20210142681A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020217033515A 2019-03-20 2020-03-20 재조합 ccn 도메인 단백질 및 융합 단백질 Ceased KR20210142681A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19163970.7 2019-03-20
EP19163970.7A EP3711772A1 (en) 2019-03-20 2019-03-20 Recombinant proteins and fusion proteins
PCT/EP2020/057773 WO2020188081A1 (en) 2019-03-20 2020-03-20 Recombinant ccn domain proteins and fusion proteins

Publications (1)

Publication Number Publication Date
KR20210142681A true KR20210142681A (ko) 2021-11-25

Family

ID=66102364

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217033515A Ceased KR20210142681A (ko) 2019-03-20 2020-03-20 재조합 ccn 도메인 단백질 및 융합 단백질

Country Status (12)

Country Link
US (1) US12606602B2 (https=)
EP (2) EP3711772A1 (https=)
JP (1) JP7600135B2 (https=)
KR (1) KR20210142681A (https=)
CN (1) CN113747912B (https=)
AU (1) AU2020243073B2 (https=)
BR (1) BR112021017147A2 (https=)
CA (1) CA3133740A1 (https=)
IL (1) IL285930B2 (https=)
MX (1) MX2021011407A (https=)
SG (1) SG11202109738QA (https=)
WO (1) WO2020188081A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259648A4 (en) * 2020-12-08 2025-03-26 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric anti-EGFR antigen receptors
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
GB202400055D0 (en) * 2024-01-03 2024-02-14 Tribune Therapeutics Ab Use of ccn domain-containing proteins for the treatment of disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1999047556A2 (en) * 1998-03-19 1999-09-23 Trustees Of Tufts College Novel heparin-induced ccn-like molecules and uses therefor
JP4202128B2 (ja) * 2000-10-16 2008-12-24 ジェネンテック・インコーポレーテッド Ｗｉｓｐポリペプチドを用いる治療方法
CN1835763B (zh) 2003-06-20 2011-04-20 妙甯公司 Ccn1组合物和方法
FR2858234B1 (fr) * 2003-08-01 2007-09-14 Centre Nat Rech Scient Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
EP1771467A2 (en) 2004-07-26 2007-04-11 Asterion Limited Linkers
ES2395260T3 (es) * 2005-01-10 2013-02-11 Rosalind Franklin University Of Medicine And Science Proteína CCN3 para su utilización en el tratamiento y el diagnóstico de enfermedades renales
DK1853631T3 (en) * 2005-01-24 2016-03-29 Univ Texas Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF
US20100144641A1 (en) 2005-09-12 2010-06-10 Popel Aleksander S Compositions Having Antiangiogenic Activity and Uses Thereof
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US20080207489A1 (en) 2007-02-21 2008-08-28 John Castellot Use of CCN5 for treatment of smooth muscle proliferation disorders
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
DK3061817T3 (en) * 2009-04-30 2019-03-04 Kao Corp Alkaline protease variants
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
CA2773737C (en) 2009-09-09 2021-11-16 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
ES2688978T3 (es) 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
KR101187814B1 (ko) 2010-03-22 2012-10-08 광주과학기술원 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
EP2552462B1 (en) 2010-04-02 2015-12-16 Rosalind Franklin University of Medicine and Science Ccn3 peptides and analogs thereof for therapeutic use
US9114112B2 (en) * 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
ES2630031T3 (es) * 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
CA2822366A1 (en) 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
WO2014008582A1 (en) 2012-07-11 2014-01-16 The University Of Western Ontario Method of treating wounds with penostin and/or ccn2
US20140271641A1 (en) 2013-03-14 2014-09-18 University Of Guelph Thrombospondin-1 polypeptides and methods of using same
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
EP3842451A1 (en) 2015-03-12 2021-06-30 MedImmune, LLC Method of purifying albumin-fusion proteins
WO2016197071A1 (en) 2015-06-05 2016-12-08 New York University Compositions and methods for anti-staphylococcal biologic agents
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
CN105396136B (zh) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用
EP3192806A1 (en) 2016-01-13 2017-07-19 Affiris AG Alpha chain of the high-affinity ige receptor (fceria)
AU2017232546B2 (en) 2016-03-14 2024-05-02 Universitetet I Oslo Engineered immunoglobulins with altered FCRN binding
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia
EP3494128B1 (en) 2016-08-04 2023-11-29 Stichting VUmc Embryonic angiogenesis markers and diagnostic and therapeutic strategies based thereon
US20180127478A1 (en) 2016-09-16 2018-05-10 Wei-Chiang Shen SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY
KR20180099537A (ko) * 2017-02-28 2018-09-05 주식회사 파이안바이오테크놀로지 근섬유모세포의 병리적 활성이 초래하는 섬유증식성 질병 치료제
KR102008407B1 (ko) 2017-09-05 2019-08-08 한국생명공학연구원 코돈 최적화된 il-21 및 이의 용도
WO2019071007A1 (en) 2017-10-05 2019-04-11 New York Genome Center, Inc. METHODS AND COMPOSITIONS FOR TARGETING VASCULAR MIMETTISM

Also Published As

Publication number Publication date
EP3711772A1 (en) 2020-09-23
MX2021011407A (es) 2022-01-24
CN113747912A (zh) 2021-12-03
US20220144903A1 (en) 2022-05-12
US12606602B2 (en) 2026-04-21
WO2020188081A1 (en) 2020-09-24
AU2020243073A1 (en) 2021-11-11
CN113747912B (zh) 2025-04-04
IL285930B2 (en) 2025-01-01
BR112021017147A2 (pt) 2021-11-09
JP2022525661A (ja) 2022-05-18
SG11202109738QA (en) 2021-10-28
EP3941507A1 (en) 2022-01-26
IL285930A (en) 2021-10-31
CA3133740A1 (en) 2020-09-24
AU2020243073B2 (en) 2025-06-05
JP7600135B2 (ja) 2024-12-16
IL285930B1 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
EP2858662B1 (en) Fibroblast growth factor 21 proteins
CN103732628B (zh) 多价杂多聚体骨架设计和构建体
JP2634323B2 (ja) Ｔｃｆ‐▲ｉｉ▼のアミノ酸配列をコードするｄｎａを含むプラスミド，形質転換細胞及びこれを用いて生理活性物質を生産する方法
ME00185B (me) Specifični agensi koji vezuju humani angiopoetin-2
KR20160038896A (ko) 성장 분화 인자 15(ｇｄｆ-15) 작제물
EP3060235B1 (en) Endoglin peptides to treat fibrotic diseases
CN110225924A (zh) 松弛素融合多肽及其用途
AU2020243073B2 (en) Recombinant CCN domain proteins and fusion proteins
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
WO2014000042A1 (en) COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
CA3000697A1 (en) Treatment of bile acid disorders
CN115379850A (zh) 再生性多肽及其用途
KR20140093942A (ko) 인간 노치1 디코이
RU2825102C2 (ru) Рекомбинантные белки с доменами ccn и слитые белки
EP2162463B1 (en) Vegf-d mutants and their use
KR20220006013A (ko) 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도
EP4166574A1 (en) Fusion protein containing erythropoietin polypeptide
WO2018112362A1 (en) Stabilized proteolytically activated growth differentiation factor 11
HK1228288B (en) Endoglin peptides to treat fibrotic diseases
HK1228288A1 (en) Endoglin peptides to treat fibrotic diseases
EA046387B1 (ru) Конструкции на основе фактора дифференцировки и роста 15 (gdf15)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601